The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for the following active substances in the context of a so-called open house procedure:

aripiprazole (N05AX12) without tablets/melt tablets/oral solutions

Fentanyl (N02AB03) without dosage forms “LUT” and “PFT”

Fingolimod (L04AA27)

Haloperidol (N05AD01)

Lacosamide (N03AX18)

Palonosetron (A04AA05)

Sorafenib (L01XE05)

Under standard contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion of a discount contract in accordance with Section 130a (8) SGB V for the active substances mentioned.

The earliest start of the contract is April 1, 2022. Based on this, the contract period is a maximum of 24 months.

Providing uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion of a discount contract in accordance with Section 130a (8) SGB V for the active substances mentioned.

The earliest start of the contract is April 1, 2022. Based on this, the contract period is a maximum of 24 months.